Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.62+0.05 (+0.12%)
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
Teva Pharmaceutical Industries operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Teva Pharmaceutical Industries's operating income for the twelve months ending Jun 30, 2026 was $1.60B, up 79.3% year over year. For fiscal 2025 it was $2.16B. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $3.95B in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16B | – |
| FY2024 | Dec 31, 2024 | -$303.00M | -170.0% |
| FY2023 | Dec 31, 2023 | $433.00M | – |
| FY2022 | Dec 31, 2022 | -$2.20B | -228.0% |
| FY2021 | Dec 31, 2021 | $1.72B | – |
| FY2020 | Dec 31, 2020 | -$3.57B | – |
| FY2019 | Dec 31, 2019 | -$443.00M | – |
| FY2018 | Dec 31, 2018 | -$1.64B | – |
| FY2017 | Dec 31, 2017 | -$17.48B | -911.7% |
| FY2016 | Dec 31, 2016 | $2.15B | -35.7% |
| FY2015 | Dec 31, 2015 | $3.35B | -15.2% |
| FY2014 | Dec 31, 2014 | $3.95B | +139.6% |
| FY2013 | Dec 31, 2013 | $1.65B | -25.2% |
| FY2012 | Dec 31, 2012 | $2.21B | -29.1% |
| FY2011 | Dec 31, 2011 | $3.11B | -19.7% |
| FY2010 | Dec 31, 2010 | $3.87B | +61.0% |
| FY2009 | Dec 31, 2009 | $2.41B | +110.0% |
| FY2008 | Dec 31, 2008 | $1.15B | -52.2% |
| FY2007 | Dec 31, 2007 | $2.40B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$231.00M | -150.8% |
| Q1 FY2026 | Mar 31, 2026 | $652.00M | +25.6% |
| Q4 FY2025 | Dec 31, 2025 | $300.00M | – |
| Q3 FY2025 | Sep 30, 2025 | $882.00M | – |
| Q2 FY2025 | Jun 30, 2025 | $455.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $519.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.00M | -103.8% |
| Q3 FY2024 | Sep 30, 2024 | -$51.00M | -114.8% |
| Q2 FY2024 | Jun 30, 2024 | -$5.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$218.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $756.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $344.00M | -18.9% |
| Q2 FY2023 | Jun 30, 2023 | -$654.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$940.00M | -1305.1% |
| Q3 FY2022 | Sep 30, 2022 | $424.00M | -31.9% |
| Q2 FY2022 | Jun 30, 2022 | -$967.00M | -266.2% |
| Q1 FY2022 | Mar 31, 2022 | -$713.00M | -264.3% |
| Q4 FY2021 | Dec 31, 2021 | $78.00M | -80.8% |
| Q3 FY2021 | Sep 30, 2021 | $623.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $582.00M | +236.4% |
| Q1 FY2021 | Mar 31, 2021 | $434.00M | +127.2% |
| Q4 FY2020 | Dec 31, 2020 | $406.00M | +174.3% |
| Q3 FY2020 | Sep 30, 2020 | -$4.34B | – |
| Q2 FY2020 | Jun 30, 2020 | $173.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $191.00M | +42.5% |
| Q4 FY2019 | Dec 31, 2019 | $148.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$81.00M | -606.3% |
| Q2 FY2019 | Jun 30, 2019 | -$644.00M | – |
| Q1 FY2019 | Mar 31, 2019 | $134.00M | -91.2% |
| Q4 FY2018 | Dec 31, 2018 | -$3.16B | – |
| Q3 FY2018 | Sep 30, 2018 | $16.00M | -95.8% |
| Q2 FY2018 | Jun 30, 2018 | -$14.00M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.53B | +70.4% |
| Q4 FY2017 | Dec 31, 2017 | -$13.02B | – |
| Q3 FY2017 | Sep 30, 2017 | $378.00M | -50.6% |
| Q2 FY2017 | Jun 30, 2017 | -$5.74B | – |
| Q1 FY2017 | Mar 31, 2017 | $895.00M | – |
| Q4 FY2016 | Dec 31, 2016 | -$137.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $765.00M | – |
See a number that looks wrong?